Comparative Pharmacology
Head-to-head clinical analysis: NORETHIN 1 35E 21 versus NYLIA 7 7 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORETHIN 1 35E 21 versus NYLIA 7 7 7.
NORETHIN 1/35E-21 vs NYLIA 7/7/7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin oral contraceptive; suppresses gonadotropin release from pituitary, inhibits ovulation, thickens cervical mucus, alters endometrial lining.
Combination of ethinyl estradiol and norethindrone; suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrial lining.
1 tablet orally once daily for 21 days, followed by 7 days off, then repeat. Each tablet contains 1 mg norethindrone acetate and 0.035 mg ethinyl estradiol.
One tablet orally once daily, with each tablet containing 0.035 mg ethinyl estradiol and sequentially 0.5 mg, 0.75 mg, 1 mg norgestimate for days 1-7, 8-14, 15-21 respectively, followed by 7 placebo days.
None Documented
None Documented
Norethindrone: terminal half-life ~7-8 hours (range 5-12 h). Ethinyl estradiol: terminal half-life ~13-27 hours (mean ~17 h). The half-life supports once-daily dosing with stable serum concentrations achieved after 3-5 days.
Terminal elimination half-life is 14 hours (range 10–18 hours). In renal impairment (CrCl <30 mL/min), half-life extends to 30–50 hours, necessitating dose adjustment.
Norethindrone and ethinyl estradiol are primarily excreted via urine (approximately 60-80% as metabolites) and feces (about 10-30%). Renal excretion accounts for the majority, with biliary/fecal elimination contributing a minor but significant fraction.
Renal (70% as unchanged drug, 10% as active metabolite), fecal (15%), biliary (5%)
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive